ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,572.07
      -0.76%
      US Tech 100
      18,922.80
      0.07%
      Dow Jones
      41,433.48
      -1.14%
      Brent Oil
      69.775
      0.09%
      Bitcoin
      83,461.50
      0.74%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Molecular Partners AG (MOLN) Quote

      Molecular Partners AG

      Molecular Partners AG (MOLN)

      NASDAQ
      4.50
      -0.1385
      (-2.99%)
      Closed March 11 4:00PM
      Delayed by 15 minutes
      4.50
      0.00
      (0.00%)
      After Hours: 4:08PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      4.50
      Bid
      4.29
      Ask
      5.42
      Volume
      8,581
      4.32 Day's Range 4.70
      0.00 52 Week Range 0.00
      Market Cap
      163.594M
      Previous Close
      4.6385
      Open
      4.49
      Last Trade
      1
      @
      4.36
      Last Trade Time
      Financial Volume
      $ 38,071
      VWAP
      4.4366
      Average Volume (3m)
      -
      Shares Outstanding
      36,354,297
      Dividend Yield
      -
      PE Ratio
      -2.48
      Earnings Per Share (EPS)
      -1.71
      Revenue
      7.04M
      Net Profit
      -61.98M

      About Molecular Partners AG

      Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseas... Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.molecularpartners.com
      Headquarters
      Schlieren, Che
      Founded
      -
      Molecular Partners AG is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MOLN. The last closing price for Molecular Partners was $4.64. Over the last year, Molecular Partners shares have traded in a share price range of $ 0.00 to $ 0.00.

      Molecular Partners currently has 36,354,297 shares outstanding. The market capitalization of Molecular Partners is $168.63 million. Molecular Partners has a price to earnings ratio (PE ratio) of -2.48.

      Ask ADVFN Intelligence (AI)

      MOLN Latest News

      More News

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      March 06 2025
      MOLN (-2.99%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      January 13 2025
      MOLN (-2.99%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      January 13 2025
      MOLN (-2.99%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10000000DR
      40000000DR
      120000000DR
      260000000DR
      520000000DR
      1560000000DR
      2600000000DR

      MOLN - Frequently Asked Questions (FAQ)

      What is the current Molecular Partners share price?
      The current share price of Molecular Partners is $ 4.50
      How many Molecular Partners shares are in issue?
      Molecular Partners has 36,354,297 shares in issue
      What is the market cap of Molecular Partners?
      The market capitalisation of Molecular Partners is USD 168.63M
      What is the 1 year trading range for Molecular Partners share price?
      Molecular Partners has traded in the range of $ 0.00 to $ 0.00 during the past year
      What is the PE ratio of Molecular Partners?
      The price to earnings ratio of Molecular Partners is -2.48
      What is the cash to sales ratio of Molecular Partners?
      The cash to sales ratio of Molecular Partners is 21.8
      What is the reporting currency for Molecular Partners?
      Molecular Partners reports financial results in CHF
      What is the latest annual turnover for Molecular Partners?
      The latest annual turnover of Molecular Partners is CHF 7.04M
      What is the latest annual profit for Molecular Partners?
      The latest annual profit of Molecular Partners is CHF -61.98M
      What is the registered address of Molecular Partners?
      The registered address for Molecular Partners is WAGISTRASSE 14, SCHLIEREN, 8952
      What is the Molecular Partners website address?
      The website address for Molecular Partners is www.molecularpartners.com
      Which industry sector does Molecular Partners operate in?
      Molecular Partners operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      RAYRaytech Holding Ltd
      $ 1.69
      (94.25%)
      		104.03M
      TSVT2seventy bio Inc
      $ 4.945
      (76.61%)
      		31.49M
      HSAIHesai Group
      $ 24.10
      (50.53%)
      		26.82M
      SPHLSpringview Holdings Ltd
      $ 6.00
      (47.06%)
      		1.63M
      SYRSSyros Pharmaceuticals Inc
      $ 0.1334
      (45.63%)
      		695.66M
      WCTWellchange Holdings Company Limited
      $ 0.68417
      (-72.74%)
      		37.5M
      ARVNArvinas Inc
      $ 8.29
      (-52.79%)
      		18.85M
      LZMHLZ Technology Holdings Ltd
      $ 8.011
      (-48.84%)
      		679.54k
      HTCOHigh Trend International Group
      $ 1.41
      (-33.80%)
      		167.52k
      SPGCSacks Parente Golf Inc
      $ 0.1061
      (-33.73%)
      		34.44M
      SYRSSyros Pharmaceuticals Inc
      $ 0.1334
      (45.63%)
      		695.66M
      BHATBlue Hat Interactive Entertainment Technology
      $ 0.0402
      (20.00%)
      		411.84M
      NVDANVIDIA Corporation
      $ 108.76
      (1.66%)
      		354.43M
      TSLLDirexion Daily TSLA Bull 2X Trust ETF
      $ 7.93
      (7.45%)
      		304.67M
      CUTRCutera Inc
      $ 0.1079
      (-16.03%)
      		218.46M

      MOLN Discussion

      View Posts
      Monksdream Monksdream 3 months ago
      MOLN, under $6


      👍️0
      OncoJock OncoJock 4 months ago
      Spoke with a research scientist today at the Memorial Sloan-Kettering Cancer Center who told me about MPO712, a radioDARPin targeted against DLL3-, which is a promising therapeutic target in a wide variety of aggressive tumors, including small cell lung cancer and the neuroendocrine form of prostate cancer. This scientist told me that there are now at least 20 drugs in development targeting DLL3, including bispecific antibodies, tri specific antibodies, radioligands, and antibody-drug conjugates. Apparently DARPins are an entirely new class of drugs, being pioneered by Molecular Partners. These drugs are characterized by structural simplicity and low molecular weight, in contrast to antibody-based drugs which are large, heavy macromolecules.

      A little research on the Molecular Partners website confirmed what the scientist told me, including that MPO712 is being prepared for entry into clinical trials in 2025. MOLN will also present posters about 2 other drugs next month at the annual meeting of the American Society of Hematology (ASH), one about MPO533 in acute myeloid leukemia, the other MPO621 an anti-CD47 agent designed as a conditioning agent for patients undergoing stem cell transplant.

      -- OJ
      👍️0
      Monksdream Monksdream 5 months ago
      MOLN under $6
      👍️0
      Awl416 Awl416 7 months ago
      Don’t blink
      👍️0
      Monksdream Monksdream 8 months ago
      MOLN
      👍️0
      Awl416 Awl416 9 months ago
      Whoops
      👍️0
      TimeFades TimeFades 9 months ago
      Short
      👍️0
      Man6677 Man6677 3 years ago
      MOLN $$$$

      https://stockcharts.com/h-sc/ui?s=MOLN


      https://finance.yahoo.com/news/molecular-partners-finalizes-license-agreement-060000110.html

      GLTA !
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Molecular Partners shares are trading higher after the company, and Novartis, reported topline data from the Phase 2 study for ensovibep, a DARPin antiviral therapeutic for COVID-19.
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
      👍️0

      Your Recent History

      NASDAQ
      MOLN
      Molecular Partners
      BIT
      P1N543
      BNP Paribas Issuance
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads